IMNN on Nasdaq

Imunon, Inc.

American pharmaceutical preparations company based in Lawrenceville.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Catabasis Pharmaceuticals, DiaMedica Therapeutics Inc. or EXICURE, INC., or pick any stock.

TickerIMNN on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address997 Lenox Drive, Suite 100, Lawrenceville, Nj 08648²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-4984.3%Operating margin³

-7179.6%Net margin³

0.0%Revenue growth, 2022³

-122.4%Return on equity⁴

0.20×Debt to equity⁵

-$23.4MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and developmentInterest

Research and development64¢$11.7M
Interest27¢$5.0M
Income tax9¢$1.6M

Out of $500.0K in revenue.³ The company lost money this year.

Financial statements

Revenue⁶⁷⁵³$500.0K in 2022+0% since 2019

Operating income⁶⁷⁵³-$24.9M in 2022+21% since 2019

Net income⁶⁷⁵³-$35.9M in 2022+113% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.¹⁰

Period ending	2025-12-31	2024-12-31
Research and development	$7.8M	$11.6M
General and administrative	$6.9M	$7.5M
Total operating expenses	$14.7M	$19.1M
Loss from operations	-$14.7M	-$19.1M
Investment income, net	$155.7K	$512.2K
Total other income, net	$155.7K	$512.2K
Net loss	-$14.5M	-$18.6M
Net loss per common share - basic	-$6.83	-$16.94
Net loss per common share - diluted	-$6.83	-$16.94
Weighted average common shares outstanding - basic	2.1M shares	1.1M shares
Weighted average common shares outstanding - diluted	2.1M shares	1.1M shares

Total assets⁶⁷⁵³$44.0M in 2022+15% since 2019

Total liabilities⁶⁷⁵³$14.6M in 2022−38% since 2019

Shareholders’ equity⁷⁵³⁴$29.3M in 2022+101% since 2019

Cash⁶⁷⁵³$11.5M in 2022+67% since 2019

Long-term debt¹¹⁶⁷⁵$6.0M in 2022−39% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.¹⁰

Period ending	2025-12-31	2025-07-31	2024-12-31	2023-12-31
Cash and cash equivalents	$8.8M		$5.9M
Advances and deposits on clinical programs and other current assets	$1.9M		$2.1M
Total current assets	$10.7M		$8.0M
Property and equipment (at cost, less accumulated depreciation and amortization)	$529.9K		$541.3K
Operating lease right-of-use assets, net	$984.4K		$1.1M
Deposits and other assets	$50.0K		$50.0K
Total other assets	$1.0M		$1.2M
Total assets	$12.3M		$9.7M
Accounts payable trade	$1.4M		$1.3M
Other accrued liabilities	$2.8M		$3.0M
Operating lease liabilities - current portion	$406.4K		$452.4K
Total current liabilities	$4.6M		$4.8M
Operating lease liabilities - non-current portion	$602.4K		$686.9K
Total liabilities	$5.2M		$5.5M
Common stock - $0.01 par value (350,000,000 and 112,500,000 shares authorized at December 31, 2025 and 2024, respectively; 3,419,652 and 966,714 shares issued at December 31, 2025 and 2024, respectively, and 3,419,650 and 966,712 shares outstanding at December 31, 2025 and 2024, respectively)	$34.2K		$9.7K
Additional paid-in capital	$428.4M		$411.1M
Accumulated deficit	-$421.3M		-$406.8M
Total stockholders equity before treasury stock	$7.1M		$4.3M
Treasury stock, at cost (2 shares at December 31, 2025 and 2024)	-$85.2K		-$85.2K
Total stockholders equity	$7.1M		$4.2M	$13.4M
Total liabilities and stockholders equity	$12.3M		$9.7M
Preferred stock, par value	$0.01		$0.01
Preferred stock, shares authorized	100.0K shares		100.0K shares
Preferred stock, shares issued	0 shares		0 shares
Preferred stock, shares outstanding	0 shares		0 shares
Common stock, par value	$0.01		$0.01
Common stock, shares authorized	350.0M shares		112.5M shares
Common stock, shares issued	3.4M shares	15 shares	966.7K shares
Common stock, shares outstanding	3.4M shares	15 shares	966.7K shares
Treasury stock, shares	2 shares		2 shares

Period ending	2025-12-31	2025-07-31	2024-12-31	2023-12-31
Cash and cash equivalents	$8.8M		$5.9M
Advances and deposits on clinical programs and other current assets	$1.9M		$2.1M
Total current assets	$10.7M		$8.0M
Property and equipment (at cost, less accumulated depreciation and amortization)	$529.9K		$541.3K
Operating lease right-of-use assets, net	$984.4K		$1.1M
Deposits and other assets	$50.0K		$50.0K
Total other assets	$1.0M		$1.2M
Total assets	$12.3M		$9.7M
Accounts payable trade	$1.4M		$1.3M
Other accrued liabilities	$2.8M		$3.0M
Operating lease liabilities - current portion	$406.4K		$452.4K
Total current liabilities	$4.6M		$4.8M
Operating lease liabilities - non-current portion	$602.4K		$686.9K
Total liabilities	$5.2M		$5.5M
Common stock - $0.01 par value (350,000,000 and 112,500,000 shares authorized at December 31, 2025 and 2024, respectively; 3,419,652 and 966,714 shares issued at December 31, 2025 and 2024, respectively, and 3,419,650 and 966,712 shares outstanding at December 31, 2025 and 2024, respectively)	$34.2K		$9.7K
Additional paid-in capital	$428.4M		$411.1M
Accumulated deficit	-$421.3M		-$406.8M
Total stockholders equity before treasury stock	$7.1M		$4.3M
Treasury stock, at cost (2 shares at December 31, 2025 and 2024)	-$85.2K		-$85.2K
Total stockholders equity	$7.1M		$4.2M	$13.4M
Total liabilities and stockholders equity	$12.3M		$9.7M
Preferred stock, par value	$0.01		$0.01
Preferred stock, shares authorized	100.0K shares		100.0K shares
Preferred stock, shares issued	0 shares		0 shares
Preferred stock, shares outstanding	0 shares		0 shares
Common stock, par value	$0.01		$0.01
Common stock, shares authorized	350.0M shares		112.5M shares
Common stock, shares issued	3.4M shares	15 shares	966.7K shares
Common stock, shares outstanding	3.4M shares	15 shares	966.7K shares
Treasury stock, shares	2 shares		2 shares

Cash from operations⁶⁷⁵³-$23.1M in 2022+14% since 2019

Capital spending⁶⁷⁵³$267.8K in 2022−23% since 2019

Free cash flow⁶⁷⁵³-$23.4M in 2022+13% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.¹⁰

Period ending	2025-12-31	2024-12-31
Net loss	-$14.5M	-$18.6M
Depreciation	$291.9K	$240.2K
Amortization of right-of-use assets	$407.0K	$477.9K
Realized losses, net, on investment securities		-$62.0K
Stock-based compensation	$127.4K	$477.3K
Fair value of shares issued in exchange for services	$99.0K
Non-cash effect of reverse stock split	$704
Realization of deferred income tax asset		$1.3M
Advances, deposits, and other current assets	$193.5K	$408.9K
Accounts payable and accrued liabilities	-$521.1K	-$3.1M
Net cash used in operating activities	-$13.9M	-$18.9M
Purchases of investment securities		-$57.2K
Proceeds from sale and maturity of investment securities		$9.9M
Purchases of property and equipment	-$280.6K	-$29.5K
Net cash (used in) provided by investing activities	-$280.6K	$9.8M
Proceeds from sale of common stock equity, net of issuance costs	$13.6M	$9.1M
Proceeds from issuance of common stock upon exercise of warrants	$3.5M
Issuance costs of stock dividend	-$10.3K
Net cash provided by financing activities	$17.1M	$9.1M
Net change in cash, cash equivalents	$2.9M	$34.2K
Recognition of operating lease right-of-use asset and liability	$274.3K

Compare Imunon, Inc. with another company

Leadership

Who has led Imunon, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Michael H. Tardugno2016–now

President

Chief financial officer

Chief operating officer

Anthony P. Deasey2006–2007

2010201520202025

Chief executive officerStacy Lindborg May 14, 2024 to now¹²
Chief executive officerGoff Corinne Le Jul 20, 2022 to Mar 21, 2023¹³
Chief executive officerMichael H. Tardugno Jan 3, 2007 to Jun 15, 2022¹⁴
Chief executive officerLawrence S. Olanoff Mar 16, 2006 to Mar 16, 2006¹⁵
ChairMichael H. Tardugno Jun 16, 2016 to now¹⁶
PresidentStacy Lindborg May 14, 2024 to now¹²
PresidentGoff Corinne Le Jul 20, 2022 to Mar 21, 2023¹³
PresidentMichael H. Tardugno Jan 3, 2007 to Jun 15, 2022¹⁴
PresidentLawrence S. Olanoff Mar 16, 2006 to Mar 16, 2006¹⁵
Chief financial officerJoshua Blacher Jul 7, 2026 to now¹⁷
Chief financial officerKimberly Bragg Jun 17, 2025 to Jul 7, 2026¹⁸
Chief financial officerDavid G. Gaiero Jun 10, 2024 to Jun 10, 2024¹⁹
Chief financial officerAnthony P. Deasey Mar 3, 2006 to Mar 19, 2007²⁰
Chief operating officerAnthony P. Deasey Mar 16, 2006 to Mar 19, 2007²¹

Board members and other officers (26)

Chief Medical OfficerDouglas Vincent Faller Feb 18, 2025 to now²²
Chief Medical OfficerSebastien Hazard Dec 11, 2023 to Dec 11, 2023²³
Chief Accounting OfficerConstantine John Kardaras Dec 16, 2021 to Jun 15, 2022²⁴
Chief Scientific OfficerKhursheed Anwer Jun 24, 2014 to now²⁵
Interim Chief Accnt OfficerTimothy J. Tumminello Jan 8, 2010 to Jun 15, 2022²⁶
VP & Chief Medical OfficerNicholas Borys Jun 17, 2008 to Feb 21, 2019²⁷
Chief Accounting OfficerPaul B. Susie Nov 21, 2007 to Mar 14, 2008²⁸
VP of Clinical DevelopmentWilliam Hahne Jan 18, 2006 to Mar 19, 2007²⁹
VP - Regulatory AffairsCarolyn Finkle Mar 16, 2006 to Mar 16, 2006³⁰
VP - OperationsMichael Oleck Mar 16, 2006 to Mar 19, 2007³¹
Board memberGoff Corinne Le Jul 20, 2022 to Mar 21, 2023¹³
Board memberJames E. Dentzer Oct 3, 2022 to now³²
Board memberStacy Lindborg Jun 8, 2021 to now³³
Board memberChristine A. Pellizzari Jun 9, 2021 to now³⁴
Board memberDonald P. Braun Dec 17, 2015 to now³⁵
Board memberAndreas Voss Dec 18, 2015 to Mar 22, 2021³⁶
Board memberFrederick J. Fritz Jul 12, 2011 to now³⁷
Board memberAlberto R. Martinez Dec 8, 2010 to Jun 16, 2020³⁸
Board memberMichael H. Tardugno Mar 19, 2008 to Feb 19, 2016³⁹
Board memberPok Yu Augustine Chow Mar 14, 2007 to Mar 21, 2023⁴⁰
Board memberWilliam Hahne Mar 14, 2006 to Mar 14, 2006⁴¹
Board memberClaude Tihon Mar 16, 2006 to Mar 16, 2006⁴²
Board memberGary W. Pace Mar 16, 2006 to Feb 23, 2010⁴³
Board memberKris Venkat Mar 16, 2006 to Dec 12, 2007⁴⁴
Board memberMax Link Mar 16, 2006 to Jun 24, 2014⁴⁵
General counselSusan Eylward Oct 7, 2024 to now⁴⁶

Former names

CELSION CORPNov 21, 2007 to Sep 19, 2022²
CHEUNG LABORATORIES INCAug 7, 1996 to Feb 17, 1998²

Timeline

May 14, 2024New chief executive Stacy Lindborg becomes CEO¹²
Jul 20, 2022New chief executive Goff Corinne Le becomes CEO¹³
Jan 3, 2007New chief executive Michael H. Tardugno becomes CEO¹⁴
Mar 16, 2006New chief executive Lawrence S. Olanoff becomes CEO¹⁵

Filings

323 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 79 major events, 152 insider forms, 12 large holders, 2 private raises, 58 other. The latest 20:

Oct 13, 20264 EDGAR
Oct 13, 20264 EDGAR
Oct 13, 20264 EDGAR
Sep 29, 20268-K EDGAR
Sep 28, 20264 EDGAR
Sep 28, 20264 EDGAR
Sep 28, 20264 EDGAR
Sep 15, 20264 EDGAR
Sep 15, 20264 EDGAR
Sep 15, 20264 EDGAR
Sep 1, 20264 EDGAR
Sep 1, 20264 EDGAR
Sep 1, 20264 EDGAR
Sep 1, 20264 EDGAR
Aug 17, 20264 EDGAR
Aug 17, 20264 EDGAR
Aug 17, 20264 EDGAR
Aug 17, 20264 EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 11, 20268-K EDGAR

The 323 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 12 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

May 27, 2025Raised $3.3 million in a private offering of equity Form D: 3 investors so far Form D
Aug 1, 2024Raised $10 million in a private offering of equity Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Armistice Capital, LLC	144,767	$257.7K	0.0%	−203,563
Riverview Capital Advisers, LLC	34,364	$247.8K	0.1%	No change
Vanguard Capital Management LLC	46,967	$83.6K	0.0%	−1,089
Geode Capital Management, LLC	31,629	$56.3K	0.0%	−1,582
Vanguard Fiduciary Trust Co	13,269	$23.6K	0.0%	No change
Northern Trust Corp	10,342	$18.4K	0.0%	New
UBS Group AG	5,203	$9.3K	0.0%	+4,628
BlackRock, Inc.	4,464	$7.9K	0.0%	No change
Tower Research Capital LLC (TRC)	3,952	$7.0K	0.0%	+2,086
Wells Fargo & Company/mn	3,342	$5.9K	0.0%	No change
Morgan Stanley	1,574	$2.8K	0.0%	−1,461
SBI Securities Co., Ltd.	1,027	$1.8K	0.0%	No change
Barclays PLC	194	$345	0.0%	New
Jpmorgan Chase & Co	134	$241	0.0%	New
Virtu Financial LLC	17,456	$31	0.0%	New
Caitong International Asset Management Co., Ltd	8	$14	0.0%	New
Group One Trading LLC	6	$11	0.0%	No change
Northwestern Mutual Wealth Management Co	3	$5	0.0%	New
Osaic Holdings, Inc.	2	$3	0.0%	No change
Fmr LLC	1	$2	0.0%	No change
Steigerwald, Gordon & Koch Inc.	1	$2	0.0%	No change
Game Plan Financial Advisors, LLC	1	$2	0.0%	No change
Royal Bank Of Canada	1	$0	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARImunon, Inc. filings on SEC EDGAR
2
SEC EDGARImunon, Inc. filings on SEC EDGAR
3
SEC EDGARImunon, Inc. 10-K for fiscal 2022
4
SEC EDGARImunon, Inc. 10-K for fiscal 2022
5
SEC EDGARImunon, Inc. 10-K for fiscal 2022
6
SEC EDGARImunon, Inc. 10-K for fiscal 2019
7
SEC EDGARImunon, Inc. 10-K for fiscal 2020
8
SEC EDGARImunon, Inc. 10-Q for fiscal 2026
9
SEC EDGARImunon, Inc. 10-Q for fiscal 2026
10
SEC EDGARImunon, Inc. 10-K filed 2026-03-31: income statement
11
SEC EDGARImunon, Inc. 10-K for fiscal 2019
12
SEC EDGARStacy Lindborg, Chief executive officer
13
SEC EDGARGoff Corinne Le, Chief executive officer
14
SEC EDGARMichael H. Tardugno, Chief executive officer
15
SEC EDGARLawrence S. Olanoff, Chief executive officer
16
SEC EDGARMichael H. Tardugno, Chair
17
SEC EDGARJoshua Blacher, Chief financial officer
18
SEC EDGARKimberly Bragg, Chief financial officer
19
SEC EDGARDavid G. Gaiero, Chief financial officer
20
SEC EDGARAnthony P. Deasey, Chief financial officer
21
SEC EDGARAnthony P. Deasey, Chief operating officer
22
SEC EDGARDouglas Vincent Faller, Chief Medical Officer
23
SEC EDGARSebastien Hazard, Chief Medical Officer
24
SEC EDGARConstantine John Kardaras, Chief Accounting Officer
25
SEC EDGARKhursheed Anwer, Chief Scientific Officer
26
SEC EDGARTimothy J. Tumminello, Interim Chief Accnt Officer
27
SEC EDGARNicholas Borys, VP & Chief Medical Officer
28
SEC EDGARPaul B. Susie, Chief Accounting Officer
29
SEC EDGARWilliam Hahne, VP of Clinical Development
30
SEC EDGARCarolyn Finkle, VP - Regulatory Affairs
31
SEC EDGARMichael Oleck, VP - Operations
32
SEC EDGARJames E. Dentzer, Board member
33
SEC EDGARStacy Lindborg, Board member
34
SEC EDGARChristine A. Pellizzari, Board member
35
SEC EDGARDonald P. Braun, Board member
36
SEC EDGARAndreas Voss, Board member
37
SEC EDGARFrederick J. Fritz, Board member
38
SEC EDGARAlberto R. Martinez, Board member
39
SEC EDGARMichael H. Tardugno, Board member
40
SEC EDGARPok Yu Augustine Chow, Board member
41
SEC EDGARWilliam Hahne, Board member
42
SEC EDGARClaude Tihon, Board member
43
SEC EDGARGary W. Pace, Board member
44
SEC EDGARKris Venkat, Board member
45
SEC EDGARMax Link, Board member
46
SEC EDGARSusan Eylward, General counsel